## RMD: ResMed Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -2.7% below STRENGTH zone (3.0-6.0%); PEG 1.57 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($233.46)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 9
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. Confluence Investment Management LLC Sells 4,405 Shares of ResMed Inc. $RMD**
- Source: MarketBeat | 20251223T100821 | Somewhat-Bullish | Relevance: 100%
- Confluence Investment Management LLC reduced its stake in ResMed Inc. by 3.8% in the third quarter, selling 4,405 shares and retaining 110,658 shares valued at approximately $30.29 million. Other institutional investors have also adjusted their holdings, with institutional ownership of ResMed currently standing at 54.98%. ResMed reported strong quarterly results, beating EPS estimates and showing a 9.1% revenue increase, and maintains a "Moderate Buy" consensus rating from analysts.

**2. The Bull Case For ResMed (RMD) Could Change Following FDA-Cleared AI Smart Comfort CPAP Feature**
- Source: Sahm | 20251222T000903 | Bullish | Relevance: 100%
- ResMed recently received FDA clearance for its AI-enabled Smart Comfort feature for CPAP devices, which personalizes settings using de-identified sleep data to improve patient adherence and ease clinician workload. This development enhances ResMed's digital health investment narrative. Investors should monitor how the company articulates its AI roadmap at upcoming conferences, weighing it against potential reimbursement changes and competitive threats.

**3. Patton Fund Management Inc. Has $265,000 Stock Holdings in ResMed Inc. $RMD**
- Source: MarketBeat | 20251223T123536 | Somewhat-Bullish | Relevance: 100%
- Patton Fund Management Inc. significantly reduced its stake in ResMed Inc. (NYSE:RMD) by 89.8% in the 3rd quarter, now holding 967 shares valued at $265,000. Meanwhile, other institutional investors like OFI Invest Asset Management and Exchange Traded Concepts LLC increased their holdings. ResMed reported strong Q3 earnings, beating analyst expectations with $2.55 EPS and $1.34 billion in revenue, and insiders have recently sold shares totaling $5.95 million.

**4. Thrivent Financial for Lutherans Acquires 5,212 Shares of ResMed Inc. $RMD**
- Source: MarketBeat | 20251222T100948 | Somewhat-Bullish | Relevance: 100%
- Thrivent Financial for Lutherans significantly increased its stake in ResMed Inc. by 75.7% in Q2, acquiring an additional 5,212 shares, bringing its total holdings to 12,099 shares valued at $3.11 million. Despite this institutional accumulation, company insiders, including a director and the CEO, collectively sold 22,662 shares worth approximately $5.95 million in the last 90 days. ResMed recently surpassed earnings estimates and maintains a "Moderate Buy" consensus rating with an average target price of $296.09 from analysts.

**5. Swedbank AB Increases Stock Position in ResMed Inc. $RMD**
- Source: MarketBeat | 20251224T131842 | Somewhat-Bullish | Relevance: 100%
- Swedbank AB significantly increased its stake in ResMed Inc. ($RMD) by 25.4% in the third quarter of 2025, now owning 542,711 shares valued at approximately $148.56 million. ResMed reported a strong quarterly earnings beat with $2.55 EPS against an expected $2.49, and revenue of $1.34 billion, marking a 9.1% year-over-year increase. The company also announced a quarterly dividend of $0.60 per share, representing a 1.0% yield.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 2)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-18 | Stifel | $260 | $270 | -4% |
| 2025-12-16 | Baird | $275 | $300 | -8% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-18 | Stifel | main | Hold |
| 2025-12-16 | Baird | down | Neutral |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 16 ($9.01M) |
| Sells | 17 ($5.01M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 37.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 3 / 6 |

**Top Holders:**
- Vanguard Group Inc: 13.1% (+1.6%)
- Blackrock Inc.: 8.4% (-1.3%)
- State Street Corpora: 4.5% (-1.0%)
- Bank Of New York Mel: 3.1% (-9.8%)
- Geode Capital Manage: 2.9% (+0.9%)

### Key Risks

1. Insider selling cluster: $5.0M in recent transactions.
2. Elevated short interest (8.2%): bears positioning against stock.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.57 elevated, pricing in significant growth expectations. Quality metrics strong (ROE 25%, ROA 14%, margin 27%). Balance sheet: strong liquidity (2.9x), low leverage (D/E 0.36). Analyst sentiment negative (2 target cuts vs 0 raises). Institutional flow bullish (3 buying vs 6 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $35.7B |
| Beta | 0.87 |
| 52W Range | $199.92 - $293.81 |
| Short Interest | 8.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.57 |
| Forward P/E | 20.3 |
| Current P/E | 22.4 |
| YoY Growth | 10.3% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from -1.7% to -2.7% (-1.1% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 5.7pp (needs >3.0% for momentum thesis). Below SMA200 (0.96x), long-term trend not supportive. RSI neutral at 42. OFD pattern: -MTL (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -2.72% (CS: 15) | Weak |
| RSI_14 | 41.8 | Neutral |
| MACD Histogram | -0.38 | Bearish |
| vs SMA20 | 0.979x | Below |
| vs SMA50 | 0.968x | Below |
| vs SMA200 | 0.963x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $244.40
- **Stop Loss:** $233.46 (4.5% risk)
- **Target:** $255.34 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 109
- **Position Value:** $26,639.60
- **Portfolio %:** 26.64%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite supported by year-end positioning. VIX at cycle lows (13.47) and multiple sectors hitting 52-week highs indicate constructive sentiment, though breadth at 57.9% suggests selectivity remains important. Fed pause expectations and stable macro backdrop support risk assets.*

### Earnings

**Next:** 2026-02-05 (Est: $2.71)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.50 | $2.55 | +2.0% |
| 2025Q2 | $2.48 | $2.55 | +2.8% |
| 2025Q1 | $2.36 | $2.37 | +0.4% |
| 2024Q4 | $2.31 | $2.43 | +5.0% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_10*